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Abstract
Therapeutics with novel modes of action and a low risk of generating resistance are urgently
needed to combat drug-resistant Plasmodium falciparum malaria. Here, we report that the
peptide vinyl sulfones WLL-vs (WLL) and WLW-vs (WLW), highly selective covalent inhibi-
tors of the P. falciparum proteasome, potently eliminate genetically diverse parasites,
including K13-mutant, artemisinin-resistant lines, and are particularly active against ring-
stage parasites. Selection studies reveal that parasites do not readily acquire resistance to
WLL or WLW and that mutations in the β2, β5 or β6 subunits of the 20S proteasome core
particle or in components of the 19S proteasome regulatory particle yield only <five-fold
decreases in parasite susceptibility. This result compares favorably against previously pub-
lished non-covalent inhibitors of the Plasmodium proteasome that can select for resistant
parasites with >hundred-fold decreases in susceptibility. We observed no cross-resistance
between WLL and WLW. Moreover, most mutations that conferred a modest loss of parasite
susceptibility to one inhibitor significantly increased sensitivity to the other. These inhibitors
potently synergized multiple chemically diverse classes of antimalarial agents, implicating a
shared disruption of proteostasis in their modes of action. These results underscore the
potential of targeting the Plasmodium proteasome with covalent small molecule inhibitors as
a means of combating multidrug-resistant malaria.
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Author summary
The spread of artemisinin-resistant Plasmodium falciparum malaria across Southeast Asia
creates an imperative to develop new treatment options with compounds that are not sus-
ceptible to existing mechanisms of antimalarial drug resistance. Recent work has identi-
fied the P. falciparum proteasome as a promising drug target. Here, we report potent
antimalarial activity of highly selective vinyl sulfone-conjugated peptide proteasome
inhibitors, including against artemisinin-resistant P. falciparum early ring-stage parasites
that are traditionally difficult to treat. Unlike many advanced antimalarial candidates,
these covalent proteasome inhibitors do not readily select for resistance. Selection studies
with cultured parasites reveal infrequent and minor decreases in susceptibility resulting
from point mutations in components of the 26S proteasome, which we model using cryo-
electron microscopy-based structural data. No parasites were observed to be cross-resis-
tant to both compounds; in fact, partial resistance to one compound often created hyper-
sensitivity to the other. We also document potent synergy between these covalent
proteasome inhibitors and multiple classes of antimalarial agents, including dihydroarte-
misinin, the clinical candidate OZ439, and the parasite transmission-blocking agent
methylene blue. Proteasome inhibitors have significant promise as components of novel
combination therapies to treat multidrug-resistant malaria.
Introduction
Plasmodium falciparum malaria threatens 40% of the world’s population, resulting in an esti-
mated 220 million cases annually. Of the ~435,000 annual malaria deaths worldwide, the
majority occur in African children below the age of five [1]. The treatment of P. falciparum
malaria is vitally dependent on artemisinin (ART) derivatives, exceptionally fast-acting anti-
malarial endoperoxides that were adopted globally nearly two decades ago as the core compo-
nents of ART-based combination therapies (ACTs) [2,3]. The rapid sweep across Asia of
parasites that display slow rates of clearance following treatment with the ART derivative arte-
sunate or with ACTs (referred to herein as ART-resistant or ART-R parasites) has created a
significant need for new treatments that can combat resistance [4–6].
Genomic, clinical epidemiologic, and genetic studies provide compelling evidence that
ART resistance is mediated primarily by mutations in the P. falciparum K13 protein [4,7–9].
K13 is a member of the BTB-Kelch family that can mediate interactions between certain E3
ubiquitin ligase complexes and substrates targeted for degradation by the ubiquitin-protea-
some system (UPS) [10,11]. In this protein family, the upstream BTB domain typically binds
the E3 ligase complex, which transfers ubiquitin moieties to the substrate protein, while the C-
terminal six-bladed β-propeller Kelch domain binds the substrate itself, conferring specificity.
While the function of P. falciparum K13 is uncharacterized, its Kelch domain harbors single
point mutations that are associated with ART resistance, including the C580Y mutation that is
predominant in Southeast (SE) Asia and the R539T mutation that confers high-level resistance
in vitro [7–9,12,13].
Several experimental studies support a connection between ART, K13 and the UPS. Tran-
scriptional profiling of ART-R SE Asian field isolates earlier revealed an upregulation of com-
ponents of the UPS in K13 mutant isolates, including several proteasome subunits [14].
Additionally, several genes associated with protein folding and trafficking to or from the ER
were upregulated, including subunits of two putative chaperone complexes—the Plasmodium
Covalent P. falciparum-specific proteasome inhibitors to treat malaria
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reactive oxidative stress complex (PROSC) and the TCP-1 ring complex (TRiC). These results
suggest that ART induces widespread protein damage, activating cell stress and proteostasis
response pathways, and that ART-R K13 mutant parasites may possess an intrinsic ability to
combat drug-induced alkylation via the repair or degradation of damaged proteins and other
biomolecules.
In support of this hypothesis, a K13 mutant Cambodian P. falciparum isolate (PL7) was
reported to show lower amounts of ubiquitinated proteins following exposure to a brief pulse
of ART as compared to a K13 wild-type (WT) Cambodian isolate (PL2) [15]. However, those
data were obtained from non-isogenic field isolates [14,15], and thus the differential responses
could be attributable to K13, or to other genetic differences. The ART metabolite DHA was
also recently reported to disrupt P. falciparum proteasome-mediated protein degradation, in
addition to generating a backlog of damaged proteins, thereby overwhelming the UPS with
substrates. Treating parasites with a translation inhibitor or with an inhibitor of E1 ubiquitin-
activating enzymes protected cells against the effects of DHA, which was attributed to the gen-
eration of fewer UPS substrates [16].
These observations have highlighted the proteasome as a novel and promising drug target
for combatting ART-R P. falciparum infections. This multi-subunit 26S complex consists of a
20S core catalytic subunit capped by 19S regulatory complexes [17]. In eukaryotes, the protea-
some contributes to diverse cellular processes ranging from cell cycle progression to apoptosis
via its tightly regulated degradation of ubiquitin-tagged substrates [18]. Initial studies of the
Plasmodium proteasome revealed that the irreversible inhibitor lactacystin blocked sporozoite
development into exoerythrocytic forms and inhibited P. falciparum asexual blood stage cell
cycle progression [19]. The proteasome inhibitor epoxomicin was also shown to be potent
against transmissible P. falciparum stage V gametocytes and to block oocyst development
within the mosquito midgut [20]. Synergy between epoxomicin and DHA was reported in P.
falciparum, as was in vivo synergy between the related epoxyketone carfilzomib and DHA in
the rodent parasite P. berghei [15]. These previous-generation inhibitors were not viable as
antimalarial therapeutics, however, due to high levels of toxicity resulting from inhibition of
the host proteasome.
Recent studies with a variety of scaffolds have sought to improve selectivity for the P. falcip-
arum proteasome [21–25]. Compounds resulting from these efforts include the covalent pep-
tide vinyl sulfone inhibitors WLL-vs and WLW-vs (referred to herein as WLL and WLW),
which are highly selective for the parasite proteasome over the human enzyme [21]. WLL also
effectively cleared a Plasmodium chabaudi rodent malaria parasite infection without signifi-
cant toxicity to the host [21]. These compounds exploit the parasite’s preference for bulky aro-
matic substrates in various positions of the β2 and β5 subunit active sites of the proteasome
[21,26]. WLL and WLW potently inhibit the β2 and β5 subunits or the β2 subunit alone,
respectively. WLW was shown to have strong activity against the ART-R PL7 isolate and the
ART-sensitive (ART-S) PL2 isolate, and showed synergy with DHA against PL7 [21]. PL7 was
~two-fold more sensitive than PL2, suggesting a possible impact of the K13 genotype.
Given the threat of multidrug-resistant P. falciparum malaria and the recognized need to
delineate the risk for parasite resistance to preclinical antimalarial candidates, we have interro-
gated mechanisms of resistance in the peptide vinyl sulfone inhibitors WLL and WLW in both
ART-S and ART-R parasites. Mutations conferring low-grade resistance were characterized
through activity-based profiling of the proteasome beta subunits and molecular modeling
based on the known cryo-electron microscopy-based structure of the P. falciparum 20S protea-
some [21]. We also screened for antimalarial agents that could overcome existing antimalarial
resistance mechanisms when combined with WLL or WLW. Our results, including the
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identification of a unique stage-specificity profile for these two proteasome inhibitors, high-
light the promising features of this class of compounds.
Results
The Plasmodium-selective proteasome inhibitors WLL and WLW are
potent against P. falciparum SE Asian parasites regardless of their K13
genotype
To examine whether the potencies of the Plasmodium-specific proteasome inhibitors WLL
and WLW were impacted by mutations in K13, we tested these two compounds against sets of
isogenic P. falciparum lines that express WT or mutant forms of this gene. Assays included the
Cam3.II (Cambodia) parental line that expresses the K13 R539T variant and that was culture-
adapted in 2010, as well as the V1/S (Vietnam) parental line that is K13 WT and that was cul-
ture-adapted in the 1970s, prior to the use of ACTs. These parental lines had previously been
edited using zinc-finger nucleases to express the K13 WT or C580Y alleles in Cam3.II para-
sites, and K13 WT, R539T or C580Y in V1/S parasites (S1 Table; [9]). These lines are referred
to herein as Cam3.II K13R539T (the unedited parental line), Cam3.II K13WT, Cam3.II
K13C580Y, V1/S K13WT, V1/S K13R539T, and V1/S K13C580Y.
Dose-response 72 hr assays with these six lines, tested as asynchronous cultures, revealed
mean half-maximal inhibitory concentrations (IC50 values) in the range of 11–13 nM for the
β2+β5 inhibitor WLL and 29–59 nM for the β2 inhibitor WLW (Fig 1A and 1B and S2
Table). When compared with isogenic WT K13 parasites, neither the C580Y nor the R539T
variants displayed altered susceptibility to either proteasome inhibitor. V1/S parasites yielded
slightly lower IC50 values than the Cam3.II lines in response to both inhibitors. For WLL, these
differences were not statistically significant. However, for WLW, Cam3.IIC580Y showed a mod-
est but nonetheless significant increase in IC50 as compared to V1/S
C580Y. Two-way ANOVA
showed a statistically significant, albeit small, difference in Cam3.II and V1/S IC50 values over-
all for WLW.
We also tested WLL and WLW against tightly synchronized early rings (0–3 hr post-inva-
sion) to determine whether K13 mutations might alter ring-stage parasite susceptibility to
Plasmodium-selective proteasome inhibitors. These experiments focused on the Cam3.II
K13WT and Cam3.II K13C580Y isogenic pair. Parasites were exposed to a 3 hr pulse of WLL or
WLW across a range of concentrations, after which the inhibitor was removed by repeated
rounds of washing (see Materials and Methods). Cultures were continued for an additional
69 hr. These assays revealed IC50 values in the range of 52–54 nM for WLL and 516–531 nM
for WLW for early rings, irrespective of their K13 genotype. We also performed 3 hr pulse
assays with synchronized Cam3.II K13WT and Cam3.II K13C580Y trophozoites, sampled 24 hr
later, which yielded substantially higher IC50 values of 422–453 nM for WLL and 1628–1698
nM for WLW. With both rings and trophozoites, we saw no difference between isogenic
Cam3.II lines expressing WT or mutant K13. Similar to the 72 hr assay, WLL was notably
more potent than WLW at both stages (Fig 1C and 1D and S3 Table).
WLL and WLW are potent inhibitors of P. falciparum early ring and
schizont stages
We next examined the sensitivity of P. falciparum to the proteasome inhibitors WLL and
WLW across the intra-erythrocytic developmental cycle by exposing tightly synchronized par-
asites to 1 hr drug pulses at specific intervals (45–47, 0–3, 10–13, 18–21 and 24–27 hr post-
invasion). These experiments were conducted on the Cam3.II K13WT and Cam3.II K13C580Y
Covalent P. falciparum-specific proteasome inhibitors to treat malaria
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Fig 1. The P. falciparum-selective peptide vinyl sulfone proteasome inhibitors WLL and WLW are highly potent
against schizonts and early ring-stage parasites irrespective of their K13 status. (A and B) Mean ± SEM IC50 values
Covalent P. falciparum-specific proteasome inhibitors to treat malaria
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isogenic pair. Parasites were exposed to fixed drug concentrations (150 nM for WLL and 2000
nM for WLW) for 1 hr, after which the inhibitor was removed by washout (see Materials and
Methods). Cultures were then continued until 72 hr from the start of the experiment. Percent
survival was calculated relative to mock (DMSO)-treated cultures. As an additional control, we
also treated parasites with DHA at 150 nM.
In these 1 hr pulse assays, mature schizonts (treated just prior to or at the time of egress)
and very early post-invasion rings were the most susceptible to proteasome inhibition by WLL
and WLW (Fig 1E and 1F). Mid to late rings and trophozoites were less susceptible, exhibiting
~five-fold higher survival rates as compared to schizonts upon exposure to either inhibitor
(Fig 1E and 1F and S4 Table). No differences were observed in the sensitivity profiles of
Cam3.II K13WT and Cam3.II K13C580Y in response to either compound.
By comparison, DHA showed a dissimilar stage-specificity profile, with maximal potency
against late rings and trophozoites. This profile coincides with the peak period of hemoglobin
uptake and degradation, during which Fe2+-heme is liberated and activates ART [27,28]. Con-
siderable inhibition was nonetheless observed in other stages, including early rings, which are
also thought to undergo some digestion of hemoglobin to activate ART [29] (Fig 1G). Against
schizonts, DHA treatment yielded almost twenty-fold higher survival levels than were
observed with trophozoites (S4 Table). In these experiments, we observed only a minor
increase in survival with K13 C580Y mutant parasites as compared to the isogenic K13 WT in
early rings in response to a 1 hr pulse of 150 nM DHA, with no difference observed at later
rings and trophozoites. Prior work has established that increasing the concentration (to 700
nM) and length of exposure (to 6 hr), in accordance with the ring-stage survival assay (RSA0-
3h), leads to a significant gain in the survival rate of the K13 C580Y mutant, specifically in early
rings [30–32].
To test the efficacy of our washout protocol, we also exposed uninfected red blood cells
(RBCs) to the same 1 hr drug pulses described above (150 nM WLL, 2000 nM WLW, 150 nM
DHA, or DMSO vehicle control). Uninfected RBCs were washed as per the 1 hr exposure
assays described above. Magnet-purified, synchronized late trophozoites were then added to
drug-treated RBCs or control (DMSO)-treated RBCs, and parasites were cultured for 48 hr to
allow for one cycle of RBC invasion and parasite growth. Parasitemias were measured by flow
cytometry and percent growth was calculated relative to DMSO control pre-treated wells.
These assays were conducted with the Cam3.II K13WT and Cam3.II K13C580Y lines. Results
showed that trophozoites added to WLL- or DHA- treated RBCs expanded to levels compara-
ble to those added to DMSO-treated RBCs (96.0% and 99.8%, respectively, when averaged
for (A) WLL or (B) WLW, tested in 72 hr dose-response assays with asynchronous parasites. These inhibitors were
assayed against Cam3.II or V1/S parasites expressing either WT K13 or the ART-resistant R539T or C580Y variants.
Assays were conducted on three to nine independent occasions in duplicate. Mann-Whitney U tests showed no
significant differences between K13 WT lines and their isogenic variants on either background. IC50 values and
statistics are reported in S2 Table. (C and D) Mean ± SEM IC50 values for (C) WLL or (D) WLW, tested in 3 hr
exposures followed by washes to remove drug and a further 69 hr of culture in drug-free medium. Parasitemias were
measured by flow cytometry. Assays were initiated with either early rings (0–3 hr post-invasion) or trophozoites
(tested 24 hr after early rings). Assays were performed with Cam3.II or V1/S lines expressing K13 WT or C580Y, on
three to four independent occasions in duplicate. Mann-Whitney U tests showed no significant differences between
K13 WT lines and their isogenic variants. Two-way ANOVA tests comparing Cam3.II and V1/S parasite lines revealed
no significant differences for WLL, and a small but significant difference for WLW. ��P value = 0.005. IC50 values and
statistics are reported in S3 Table. (E-G) Tightly synchronized Cam3.II parasites expressing K13 WT or C580Y were
treated for 1 hr with (E) 150 nM WLL, (F) 2000 nM WLW, or (G) 150 nM DHA at five intervals, beginning with
distinct stages. Drug was removed by washing and cultures were continued for a further 71 hr in drug-free medium
prior to measuring parasitemias. Data are shown as mean ± SEM percent survival for drug-treated parasites, calculated
relative to DMSO vehicle-treated cultures tested in parallel. Assays were performed on three (WLL and WLW) or two
(DHA) independent occasions in duplicate. Percent survival values are reported in S4 Table.
https://doi.org/10.1371/journal.ppat.1007722.g001
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across K13 WT and K13 C580Y lines and across three independent experiments; S5 Table).
These data show that WLL and DHA were both effectively washed out to sub-inhibitory con-
centrations (Fig 1E and 1G). By comparison, trophozoites inoculated into WLW-treated
RBCs had reduced growth (79.7% on average across both lines relative to the DMSO control;
S5 Table), which suggests that some of the inhibition observed in parasites treated with the
high-dose of WLW (Fig 1F) may be attributable to drug carryover. Nonetheless, the inhibition
profile observed for both WLL and WLW across stages was consistent, with both inhibitors
showing maximal inhibition in schizonts and early ring stages, contrasting with maximum
survival at the mid to late ring stage (Fig 1E and 1F and S4 Table).
Parasites show a limited propensity for acquiring resistance to WLL or
WLW
To evaluate the ability of P. falciparum to generate resistance to the proteasome inhibitors
WLL and WLW, we exposed cultured parasites to sub-lethal concentrations of WLL or WLW
(at either three or five times the IC50 level) for a period of up to 60 days. Selection studies were
performed with the two pairs of isogenic K13 WT and C580Y lines: Cam3.II K13WT and
Cam3.II K13C580Y, and V1/S K13WT and V1/S K13C580Y. Selections were performed in tripli-
cate, each with a large starting inoculum of 2×109 parasites per flask. Parasite clearance was
confirmed during the first six days of treatment and subsequent recrudescence of parasitemia
was monitored by microscopy two to three times a week.
Initial studies using 5×IC50 drug pressure for WLL showed very low levels of recrudescence,
with only 2 of 12 selection flasks resulting in detection of parasites by day 60 (Table 1). Sur-
vival in the presence of WLW occurred more readily, with 6 of 12 flasks yielding recrudescent
parasites. In the case of WLL, recrudescent parasites did not appear until day 51, whereas with
WLW the mean time to recrudescence was 34 days for Cam3.II parasites and 27 days for V1/S
Table 1. In vitro resistance selections.
Parasite line Compound Selection pressurea Positive flasksb Day first positivec
Cam3.II K13WT WLL 5×IC50 0 of 3 —
Cam3.II K13C580Y WLL 5×IC50 0 of 3 —
V1/S K13WT WLL 5×IC50 0 of 3 —
V1/S K13C580Y WLL 5×IC50 2 of 3 51, 51
Cam3.II K13WT WLL 3×IC50 0 of 3 —
Cam3.II K13C580Y WLL 3×IC50 2 of 3 35, 35
V1/S K13WT WLL 3×IC50 1 of 3 41
V1/S K13C580Y WLL 3×IC50 3 of 3 32, 38, 38
Cam3.II K13WT WLW 5×IC50 0 of 3 —
Cam3.II K13C580Y WLW 5×IC50 1 of 3 33
V1/S K13WT WLW 5×IC50 2 of 3 27, 27
V1/S K13C580Y WLW 5×IC50 3 of 3 27, 27, 27
Cam3.II K13WT WLW 3×IC50 3 of 3 34, 34, 34
Cam3.II K13C580Y WLW 3×IC50 3 of 3 34, 34, 34
V1/S K13WT WLW 3×IC50 3 of 3 24, 24, 26
V1/S K13C580Y WLW 3×IC50 3 of 3 29, 29, 31
aIC50 values for WLL and WLW are reported in S2 Table.
bSelections were performed with triplicate flasks each harboring an initial inoculum of 2×109 asexual blood stage parasites.
cCultures were stopped at Day 60 in the absence of recrudescence, indicating that no resistance was obtained.
https://doi.org/10.1371/journal.ppat.1007722.t001
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parasites. A second round of selections performed under 3×IC50 drug pressure resulted in
greater levels of recrudescence, with 6 of 12 WLL flasks and 12 of 12 WLW flasks yielding par-
asites within 24–41 days (Table 1). These results also suggested a lower propensity for the
Cambodian Cam3.II line to develop resistance compared with V1/S (9 of 24 selections yielded
parasites compared with 17 of 24, respectively). These data are consistent with earlier findings
that V1/S was ~two-fold more mutable than Cam3.II [33] (Cam3.II was referred to therein as
PH0306-C). Of note, K13 C580Y parasites were twice as likely to have positive selection out-
comes when compared with K13 WT parasites (17 of 24 selections compared with 9 of 24 sepa-
rate selections, respectively; Table 1), suggesting that the K13 C580Y mutation might also
modestly increase the mutation rate.
Whole-genome sequencing of WLL- or WLW-pressured parasites identifies
point mutations in proteasome subunits
To identify genetic changes mediating parasite recrudescence following WLL and WLW selec-
tion, we performed Illumina-based whole-genome sequencing on the drug-pressured recru-
descent lines and their four parental counterparts. In total, ten unique mutations were
identified from the 26 recrudescent lines (Table 2 and S6 Table). Four of the eight WLL-
selected parasite lines harbored a mutation in the β5 subunit of the 20S proteasome core parti-
cle, resulting in an alanine to serine substitution at amino acid position 20 (A20S) in the
mature protein, while the other four harbored mutations in the 20S proteasome β6 subunit,
yielding either an alanine to valine change at position 117 (A117V) or a serine to leucine sub-
stitution at position 208 (S208L) (Table 2 and S6 Table). 14 of 18 (78%) of WLW-selected par-
asite lines harbored a mutation in the 20S proteasome β2 subunit. These changes included a
cysteine to phenylalanine or a cysteine to tyrosine mutation at position 31 (C31F or C31Y),
and an alanine to glutamic acid substitution at position 49 (A49E). The four remaining lines
selected against WLW harbored mutations in the 19S regulatory particle of the 26S protea-
some. These mutations included a premature stop codon in RPT4 (E380�), two non-synony-
mous mutations in RPT5 (R295S and G319S), and a non-synonymous mutation in RPN6
(E266K) (Table 2 and S6 Table).
Table 2. Mutations identified by whole-genome sequencing of WLL- or WLW-pressured parasite lines.
Gene ID Protein name Mutation pre-processinga Mutation in mature proteinb Selection compound Frequencyc
PF3D7_1011400 20S β5 subunit A80S A20S WLL 4/8
PF3D7_0518300 20S β6 subunit A117V A117V WLL 3/8
PF3D7_0518300 20S β6 subunit S208L S208L WLL 1/8
PF3D7_1328100 20S β2 subunit C72F C31F WLW 7/18
PF3D7_1328100 20S β2 subunit C72Y C31Y WLW 6/18
PF3D7_1328100 20S β2 subunit A90E A49E WLW 2/18
PF3D7_1306400 19S RPT4 NA E380� WLW 2/18
PF3D7_1130400 19S RPT5 NA G319S WLW 1/18
PF3D7_1130400 19S RPT5 NA R295S WLW 1/18
PF3D7_1402300 19S RPN6 NA E266K WLW 2/18
aAmino acid change in protein prior to proteolytic processing.
bAmino acid change in mature protein (post-processing).
cFraction of total drug-selected lines that acquired the designated mutation.
NA, not applicable (protein does not undergo post-translational processing).
https://doi.org/10.1371/journal.ppat.1007722.t002
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In the 26 sequenced drug-pressured lines, we observed no other mutations at�20% allele
frequency in the core genome (which removes sub-telomeric regions and members of multi-
gene family members [34]). This observation further supports a primary role for the 19S and
20S proteasome mutations described above in mediating resistance. Copy number variation
(CNV) analysis of the 26 lines detected amplification of a putative ubiquitin regulatory protein
(PF3D7_0808300) in two recrudescent lines. In both cases, the amplification occurred in V1/S
K13C580Y parasites selected at 3×IC50 drug pressure with either WLL or WLW (S6 Table; flask
R2 in both cases), suggesting that this gene may contribute to low-grade resistance to WLL
and WLW. Both drug-pressured lines also harbored single nucleotide polymorphisms in the
20S proteasome β5 (A20S) or β2 (A49E) subunits, providing evidence that the ability of para-
sites to withstand drug pressure in the bulk cultures can be multifactorial. As a quality control
for our CNV analysis, we confirmed that the V1/S and Cam3.II genomes differed at the GTP
cyclohydrolase locus (PF3D7_1224000) that is amplified in V1/S parasites (contributing to
high-grade pyrimethamine resistance; [35,36]). We also observed that V1/S parasites harbor a
chromosome nine deletion that was previously associated with loss of cytoadhesion [37]. For
these lines, the mean genome coverage was 54-fold (range 16–85; S6 Table).
WLL- or WLW-selected lines display small IC50 increases and no cross-
resistance between inhibitors
From the set of WLL- or WLW-selected lines, we selected nine for 72 hr dose-response assays.
Lines that contained a given proteasome mutation at� 90% allele frequency were assayed
directly without cloning, whereas lines that displayed mixed parasite populations were first
cloned by limiting dilution. These lines are referred to herein by their unique proteasome
mutations and are grouped by their respective parent: RPT4 E380� and RPN6 E266K (selected
in the Cam3.II K13WT parental line); β5 A20S, β2 C31Y and RPT5 G319S (Cam3.II K13C580Y);
β6 A117V and β2 C31F (V1/S K13WT); and β6 S208L and β2 A49E (V1/S K13C580Y; S7 Table).
In parallel, we also assayed the four parental lines: Cam3.II K13WT, Cam3.II K13C580Y, V1/S
K13WT, and V1/S K13C580Y. Results are shown in Fig 2, in which K13 WT and K13 C580Y
lines are colored blue and red, respectively. WLL-selected and WLW-selected lines are shown
with thin and thick hatching, respectively.
WLL-selected lines harboring β5 A20S or β6 A117V mutations were observed to confer
small (~two-fold) but nonetheless statistically significant increases in WLL IC50 levels com-
pared with their parental lines (Fig 2A and S8 Table), and slightly higher increases (up to
three-fold) in the WLL 90% inhibitory concentration (IC90 value; S9 Table). The WLL-
selected β6 S208L line showed only very modest (<two-fold) and not statistically significant
increases in WLL IC50 and IC90 values (Fig 2A and S8 Table and S9 Table). By comparison,
WLW-selected lines harboring a β2 subunit mutation (C31Y, C31F and A49E) revealed
slightly larger shifts (~three- to five-fold) in their WLW IC50 values compared to their parental
lines (Fig 2B and S8 Table). WLW-selected lines harboring mutations in the 19S proteasome
regulatory particle (RPT4 E380�, RPN6 E266K, and RPT5 G319S) displayed small (~two-fold)
but significant increases in IC50 values compared with their parental lines. These trends were
maintained at the IC90 level (S9 Table).
We next evaluated the ability of mutations identified in WLW-selected lines to confer resis-
tance to WLL and vice versa. Surprisingly, we observed that the β2 C31F and β2 C31Y lines
(both WLW-selected) were hypersensitive to inhibition by WLL, despite the fact that WLL
inhibits both the β2 and β5 subunits of the parasite proteasome. The third β2 mutant line, β2
A49E, showed no shift in WLL IC50 or IC90 as compared to the parental line. Similarly, none
of the 19S mutant lines displayed any cross-resistance to WLL (Fig 2A and S8 Table and S9
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Table). The three mutations identified in WLL-pressured lines affected sensitivity to WLW in
distinct ways: whereas the β5 A20S line showed significant hypersensitization to WLW, the β6
A117V line showed a minor (2.5-fold) increase in WLW IC50 as compared to the parental line.
Finally, the β6 S208L mutation did not result in any significant shift in WLW IC50 or IC90 val-
ues (Fig 2B and S8 Table and S9 Table).
Structure-based modeling suggests that mutations induce conformational
rearrangements in the β2, β5 and β6 subunits
To simulate the effects of mutations in the β2, β5 and β6 subunits on WLL and WLW binding
in silico, we performed structural analyses with both inhibitors using the high resolution cryo-
EM based structure of the P. falciparum 20S proteasome (PDB accession code 5FMG). For
these studies, we docked WLL into the β5 active site of the cryo-EM-based atomic model of
the P. falciparum 20S proteasome (Fig 3A and 3B) and for WLW used the previously solved
structure of the inhibitor bound to the β2 active site (Fig 3F and 3G) [21]. As expected, dock-
ing studies revealed that WLL was well-accommodated within the β5 active site (Fig 3B).
To examine the effect of the WLL-selected mutations β5 A20S and β6 A117V and S208L,
we used molecular dynamics simulations to individually evaluate the effects of these mutations
on the β5 active site (Fig 3C–3E). For the β5 A20S mutation, the introduction of a serine side
chain was predicted to directly impose steric constraints on the S3 binding pocket of the β5
active site. These constraints would not favor large groups at the P3 position of the ligand,
such as the P3 tryptophan of WLL. The β6 A117V mutation was predicted to destabilize a clus-
ter formed by three tyrosine residues at positions 150, 152 and 158 of β6, inducing a slight dis-
placement of the β strands of the β6 subunit towards the β5 binding pocket. This
conformational change would produce steric constraints on the β5 active site binding pocket,
Fig 2. WLL- and WLW-pressured mutant parasite lines display modest gains of resistance. (A and B) Mean ± SEM IC50 values are
shown for the Cam3.II or V1/S lines expressing (blue) WT or (red) C580Y K13, exposed to (A) WLL or (B) WLW for 72 hr. Assays were
performed on five to seven independent occasions in duplicate. Shown above each bar is the compound used for resistance selections
(thin hatching, WLL-selected; thick hatching, WLW-selected). Mutant lines (see Table 2 and S7 Table) are illustrated beside their
parental drug-sensitive line. Statistical significance was examined using Mann-Whitney U tests. ��P value<0.01; ns, not significant. IC50
and IC90 values and associated statistics are reported in S8 Table and S9 Table, respectively.
https://doi.org/10.1371/journal.ppat.1007722.g002
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Fig 3. In silico modeling of 20S β2, β5 and β6 mutations reveals disruption of inhibitor binding. (A-E) Modeling
of WLL binding. (A) Structure of the WLL peptide-based inhibitor, indicating positions P1-P3 and the electrophilic
vinyl sulfone warhead that reacts with the β5 subunit catalytic threonine residue (Thr1). (B-E) Docking of WLL into
the β5 active site. The β5 and β6 subunits are shown in light blue and dark blue, respectively. Arrows highlight the P3
tryptophan residue of the ligand. (B) Docking of WLL into the WT β5 site of the cryo-EM derived P. falciparum 20S
proteasome model. (C-E) Docking of WLL into the β5 active site of molecular dynamics-simulated models with the
WLL-selected mutations, namely (C) β5 A20S (D) β6 A117V and (E) β6 S208L, demonstrating their potential impact
on WLL binding. (F-J) Modeling of WLW binding. (F) Structure of the WLW peptide-based inhibitor, indicating
positions P1-P3 and the electrophilic vinyl sulfone warhead that reacts with the β2 subunit catalytic threonine residue
(Thr1). (G-J) Docking of WLW into the β2 active site. The β2 and β3 subunits are shown in orange and green,
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particularly for access of the WLL P3 group, as recently suggested for the similar β6 A117D
substitution [23]. For the β6 S208L mutation, introduction of the leucine side chain in β6 was
predicted to cause a significant clash with the adjacent α helix in the β3 subunit. This substitu-
tion induced conformational rearrangements in the model that were able to propagate as far as
the S3 site of the β5 binding pocket. These changes would again impose steric constraints on
WLL binding (Fig 3C–3E). The rearrangements induced by the WLL-selected mutations were
all characterized by smaller, sterically-constrained β5 binding pockets, particularly at the S3
position, as compared with the WT Plasmodium proteasome β5 active site.
We also modeled the WLW-selected β2 mutations, namely C31Y, C31F and A49E, using
the known cryo-EM based P. falciparum 20S proteasome structure (5FMG; [21]). The three
mutated residues are located near the S1 binding pocket of the β2 active site. The introduction
of bulky tyrosine or phenylalanine residues in place of the cysteine at position 31 was predicted
to cause a steric clash with the large P1 tryptophan of WLW, likely preventing binding of
WLW to the β2 subunit (Fig 3H and 3I). Similarly, the β2 A49E mutation was predicted to
produce steric constraints near the S1 binding pocket caused by the introduction of the bulky
glutamate side chain (Fig 3J). Structural modeling suggested that these β2 mutants should still
retain sensitivity to WLL, which has a smaller P1 side chain compared to WLW. These predic-
tions are consistent with the lack of cross-resistance between the WLW-selected mutants and
WLL; in fact, the β2 C31Y and C31F mutant lines selected under WLW pressure showed
hypersensitivity to WLL (Fig 2).
Activity-based probe labeling reveals inhibitor interactions with
proteasome subunits that are affected by mutations in drug-pressured lines
We next examined whether mutations in the 20S proteasome subunits confer resistance to
WLL or WLW by directly precluding binding of the inhibitors to the active sites of the protea-
some. These experiments involved activity-based probe (ABP) labeling of the three catalytic
subunits β1, β2 and β5 using the proteasome active-site fluorogenic probe BMV037
([26,38,39]; see Materials and Methods). This probe competes for binding with proteasome-
specific inhibitors including WLL and WLW, which allows for direct assessment of inhibitor
binding to each of the active beta subunits of the proteasome through the quantification of
residual protein labeling after inhibitor treatment.
Competition assays were performed for the three WLL-selected lines harboring β5 or β6
mutations (β5 A20S, β6 A117V, and β6 S208L) and the three WLW-selected lines harboring
mutations in β2 (C31Y, C31F and A49E). P. falciparum schizont lysates from the six test lines
and their respective parents were pre-incubated for 1 hr with WLL or WLW at concentrations
ranging from 0.5 to 50 μM, or mock-treated, then incubated for 2 hr with the BMV037 probe.
In the absence of either inhibitor, the probe showed similar labeling regardless of whether
lines carried mutations in the proteasome subunits or not (Fig 4A). In the presence of increas-
ing concentrations of WLL or WLW, probe labeling of the β2 and β5 subunits was reduced by
the binding of these inhibitors. To quantify this effect, we calculated the concentration at
which WLL or WLW achieved half-maximal inhibition of probe labeling to each subunit
(shown as IC50 values in Fig 4B–4D and S10 Table; see Materials and Methods). For the
WLL-selected lines, the β5 A20S mutation had a small effect on WLL binding to β5,
respectively. Arrows highlight the P1 tryptophan residue of the ligand. (G) Docking of WLW into the WT β2 site of the
cryo-EM derived P. falciparum 20S proteasome model. (H-J) Docking of WLW into the β2 active site of the
superposed WLW-selected mutation models, i.e. (H) β2 C31F (I) β2 C31Y and (J) β2 A49E, and their potential impact
on WLW binding.
https://doi.org/10.1371/journal.ppat.1007722.g003
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manifesting as a slight increase in the WLL β5 IC50 (Fig 4A and 4C). This result is consistent
with our structural analysis. This mutation, however, did not impact inhibition of the β2 sub-
unit by either WLL or WLW (Fig 4A, 4B and 4D). The WLL-selected β6 mutation A117V
slightly reduced the potency of WLL in blocking the labeling of the β5 subunit by BMV037,
whereas the β6 S208L mutation appeared to have a minor effect on WLL binding to β2. These
two β6 mutations did not substantially affect binding of WLW to the β2 active site (Fig 4A–
4D).
For the WLW-selected lines, the β2 C31Y and C31F mutations both reduced WLW binding
to the β2 active site, but did not prevent WLL binding to β2 (Fig 4A–4D). This finding agrees
with our structural analysis, which shows a preference against mutant site occupancy by the
large tryptophan P1 group of WLW. This also explains why the WLW-selected mutants were
not resistant to WLL, which has a leucine in the P1 position. The third WLW-selected β2
Fig 4. Activity-based probe profiling of 20S β2 and β5 active sites permits quantification of the impact of 20S
subunit mutations on inhibitor binding. (A) P. falciparum schizont lysates treated for 1 hr with WLL or WLW at
concentrations ranging from 0.5 to 50 μM, or mock-treated with DMSO, then incubated for 2 hr with the BMV037
probe. Samples were run on 12% SDS-PAGE gels. Data show results from one representative experiment. (B-D) Bar
charts showing the concentrations at which WLL or WLW achieved half-maximal inhibition of probe labeling to each
subunit. Data are shown as mean ± SEM IC50 values from two independent experiments (of which one is shown in
panel A). (B) Inhibition of β2 subunit by WLL; (C) Inhibition of β5 subunit by WLL (D); inhibition of β2 subunit by
WLW. IC50 values are reported in S10 Table.
https://doi.org/10.1371/journal.ppat.1007722.g004
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mutation, A49E, also prevented WLW binding to β2, but not as strongly as C31Y or C31F.
This mutation resulted in a reduction of WLL binding to β2, which is consistent with the prox-
imity of this mutation to the entrance of the β2 binding pocket [40]; Fig 4A–4D).
Proteasome inhibitors WLL and WLW synergize with multiple classes of
antimalarial agents
To test for interactions between WLL or WLW and other classes of antimalarials, we per-
formed isobologram assays with the isogenic ART-S Cam3.II K13WT and ART-R Cam3.II
K13C580Y lines. These assays included DHA, the related endoperoxide-containing compound
OZ439 that is suspected to have a similar mode of action [41,42], methylene blue (MB) that
disrupts redox homeostasis, and two compounds implicated in pathways related to the UPS,
namely b-AP15 that inhibits proteasome-associated deubiquitinases, and eeyarestatin I (ESI)
that inhibits the ER-associated degradation (ERAD) pathway (S11 Table). Assays were initi-
ated with either asynchronous parasites that were exposed to drugs for 72 hr, or with synchro-
nized early rings (0–3 hr post-invasion) or trophozoites (tested 24 hr later) that were exposed
to drugs for 3 hr followed by three rounds of drug washout and a further 69 hr of incubation
in drug-free medium prior to measuring parasitemias. Drug combinations were tested at fixed
ratios (1:0, 4:1, 2:1, 1:1, 1:2, 1:4, 0:1) across a range of concentrations (see Materials and Meth-
ods). From these data, we derived fractional IC50 (FIC50) values for the two compounds at
each of the ratios tested, and plotted these values on isobologram graphs. The shapes of the
resulting curves were then compared against a hypothetical isobole line illustrating a perfectly
additive interaction (dashed line in Fig 5). With these graphs, a concave curve with points
lying substantially below the isobole line is evidence of synergy, whereas points near the iso-
bole line indicate additivity, and a convex curve with points lying substantially above the iso-
bole line indicates antagonism.
Our drug combination studies provided clear evidence of synergy between WLW and
DHA, OZ439, MB and b-AP15, for both the ART-S and ART-R isogenic lines (Fig 5). These
results were obtained with asynchronous parasites, as well as synchronized early post-invasion
rings and trophozoites. Rings showed the clearest evidence of synergy, as evidenced by the
most concave curves. This finding was particularly significant as rings are generally the least
susceptible to antimalarial drugs including ART derivatives (Fig 1G; [43]), with the notable
exception of proteasome inhibitors that our data show are the most potent against this stage.
Mild synergy was observed between WLW and ESI at the early ring stage, however the interac-
tion between these two compounds was additive on asynchronous parasites and on trophozo-
ites (Fig 5). Synergy was also evidenced with DHA, OZ439 and b-AP15 in combination with
WLL on early rings and trophozoites, though to a reduced degree as compared with WLW (S1
Fig). For MB, synergy with WLL was limited to the early ring stage, and for ESI, the interaction
with WLL was largely additive (S1 Fig).
We extended our isobologram studies to the mitochondrial inhibitor atovaquone (ATQ),
the licensed ACT partner drugs and suspected heme-interacting agents lumefantrine (LMF)
and piperaquine (PPQ), and the former first-line antimalarial chloroquine (CQ; S11 Table).
Additive to antagonistic profiles were observed between the proteasome inhibitors and these
four compounds. Results for these compounds and those tested above are shown as the mean
of the sums of the fractional IC50 values of the combinations (mean SFIC50) and are repre-
sented as heat maps (Fig 6; values tabulated in S12 Table). A mean value less than or equal to
0.5 indicates that the interaction between the two compounds was potently synergistic (blue),
a mean close to 1.0 is indicative of an additive interaction (white), and a mean greater than or
equal to 1.5 indicates potent antagonism (red). These thresholds are rarely met with P.
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falciparum, in part because such interactions manifest the most clearly only at certain combi-
nation ratios [21,44–46]. Mean SFIC50 values lying between these cutoffs, i.e. greater than 0.5
but less than 1.0, or greater than 1.0 but less than 1.5, suggest mild synergy or mild antagonism,
respectively.
For LMF, mild antagonism was observed on asynchronous parasites with WLL or WLW,
while these interactions were largely additive on early rings and trophozoites. For PPQ and
ATQ, the antagonism observed in asynchronous parasites and early rings was attenuated in
trophozoites. For CQ, moderate to potent antagonism was observed across all stages (Fig 6A–
Fig 5. WLW synergizes with multiple classes of structurally and functionally diverse antimalarials. Isobolograms of WLW and (in descending
order) DHA, OZ439, MB, b-AP15 and ESI tested on asynchronous parasites and highly synchronized rings and trophozoites. Cam3.II K13
WT or
Cam3.II K13C580Y parasites were exposed to compounds mixed at fixed ratios of their individual IC50 values (1:0, 4:1, 2:1, 1:1, 1:2, 1:4, 0:1).
Asynchronous parasites were exposed for 72 hr and parasitemias were determined by flow cytometry. Highly synchronized rings (0–3 hr post-
invasion) or trophozoites (tested 24 hr later) were exposed for 3 hr, followed by drug washouts and continued culture for 69 hr in drug-free media.
Fractional IC50 (FIC50) values were plotted for each drug combination and fixed ratio and results were compared against a hypothetical isobole line
illustrating a perfectly additive interaction (dashed line). Data show results of two independent isobologram assays (shown in different shades), each
performed in duplicate, tested against Cam3.II K13WT (blue) and Cam3.II K13C580Y (red). Synergy is evidenced by individual FIC50 pairwise values
falling below the dashed line of additive interactions (FIC50 = 1). DHA, dihydroartemisinin; ESI, eeyarestatin I; MB, methylene blue.
https://doi.org/10.1371/journal.ppat.1007722.g005
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6C). These heat maps visually illustrate the potent synergy observed with DHA, OZ439, MB
and b-AP15 (Fig 5).
We also tested a panel of experimental compounds with diverse targets and modes of
action, including AN3661, an inhibitor of the P. falciparum cleavage and polyadenylation spec-
ificity factor subunit 3; ACT-451840, suspected to inhibit PfMDR1; cycloheximide, an inhibi-
tor of tRNA translocation and protein synthesis; DDD107498, an inhibitor of P. falciparum
translation elongation factor 2; DSM265, a dihydroorotate dehydrogenase inhibitor; halofugi-
none, a prolyl tRNA synthetase inhibitor; and NITD609, an inhibitor of P. falciparum P-type
Na+ ATPase 4 (S11 Table) [47–53]. Each compound showed antagonism with WLL and
Fig 6. WLL and WLW show differential interactions with distinct classes of antimalarials, including synergy with
DHA and the related ozonide OZ439, and antagonism with CQ and PPQ. (A-C) Heat maps of interactions between
the WLL or WLW proteasome inhibitors and distinct antimalarial agents. Assays used the Cam3.II K13WT and Cam3.
II K13C580Y lines. Parasites were exposed to compounds mixed at fixed ratios of their individual IC50 values (1:0, 4:1,
2:1, 1:1, 1:2, 1:4, 0:1). (A) Asynchronous parasites were exposed for 72 hr and parasitemias were determined by flow
cytometry. (B) Highly synchronized rings (0–3 hr post-invasion) or (C) trophozoites (tested 24 hr later) were exposed
for 3 hr, followed by drug washouts and continued culture for 69 hr in drug-free media. Values represent the mean of
the sums of the FIC50 values over the five fixed ratios of the two test compounds (excluding the 1:0 and 0:1 points).
Assays were conducted on two to four independent occasions in duplicate. Data for WLW and the five top compounds
(DHA, OZ439, MB, b-AP15 and ESI) are presented as isobolograms in Fig 5. ATQ, atovaquone; CQ, chloroquine;
DHA, dihydroartemisinin; ESI, eeyarestatin I; LMF, lumefantrine; MB, methylene blue; PPQ, piperaquine. Means of
the sums of FIC50 (mean SFIC50) values are reported in S12 Table.
https://doi.org/10.1371/journal.ppat.1007722.g006
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WLW. No substantial differences were observed in the responses of K13 WT versus K13
C580Y parasites to any of these compounds (S2 Fig and S13 Table).
Discussion
The evolution of drug-resistant P. falciparum parasites has severely compromised prior-gener-
ation first-line antimalarials such as CQ, with devastating consequences. Resistance is also
increasingly undermining the efficacy of ACTs in SE Asia. The search for new antimalarials
has uncovered a spectrum of novel scaffolds active against specific parasite targets, including
mitochondrial factors (DHODH, cytochrome B), the Na+-ATPase PfATP4, the cis-Golgi pro-
tein PfCARL, several cytosolic tRNA synthetases, and the eukaryotic elongation factor PfeEF2
[54,55]. Nonetheless, despite their nanomolar potency, many of these inhibitors can readily
select for resistance via mutations in their respective target proteins, sometimes with as few as
106 or 107 parasites. Also, depending on the target and inhibitor, the IC50 increases observed
in resistant parasites can vary from several fold up to two thousand-fold [54]. These findings
can have direct implications for treatment outcomes in vivo, as recently evidenced in a clinical
trial where two of 24 P. falciparum-infected patients treated with a low single dose of DSM265
recrudesced with parasites that had acquired DHODH mutations previously observed in
DSM265 resistance selections in vitro [56].
Here, we report that the Plasmodium proteasome-specific peptide vinyl sulfone inhibitors
WLL and WLW have low nanomolar potency against genetically diverse parasites, are equally
effective against parasites expressing mutant or WT forms of the ART resistance determinant
K13, and display a unique stage-specificity profile. Stage-specificity assays reveal WLL and
WLW to be most potent against schizonts and early ring stages. This finding is particularly
promising as the majority of currently-employed antimalarials are most active against the tro-
phozoite stage, including ART derivatives (which also inhibit rings) [43]. Importantly, we also
observe a minimal resistance liability with WLL and WLW. Inocula of 2 × 109 parasites
exposed to low drug levels yielded recrudescent parasites in only half the selections, with IC50
increases averaging <three-fold (Table 1 and S8 Table). WLL- or WLW-resistant lines
retained full sensitivity to the alternate inhibitor, and in several cases mutations that conferred
resistance to one inhibitor sensitized parasites to the other. This finding suggests that resis-
tance is highly compound-specific and that selective pressures exerted by different inhibitors
even within the same series can act in opposing directions. The different selectivity of WLL
and WLW was confirmed by activity-based profiling of the proteasome catalytic sites in para-
sites harboring mutations in β2, β5 or β6, which revealed that WLL-selected mutations inter-
fered specifically with binding of WLL and not WLW, and vice versa. We also leveraged the
existing high-resolution cryo-EM structure of the P. falciparum 20S proteasome [40] to per-
form in silico modeling, which predicted that mutations in the β2, β5 and β6 subunits could
specifically reconfigure proteasome active sites in the 20S core particle to confer compound-
selective resistance. Gene-editing studies, which would provide an additional layer of confir-
mation, have not yet been undertaken.
Of note, a recent study of noncovalent, reversible asparagine ethylenediamine (AsnEDA)
20S proteasome inhibitors reported parasites that were cross-resistant to several AsnEDA inhib-
itors but were hypersensitized to the pan-active proteasome inhibitors bortezomib and carfilzo-
mib, as well as to WLW [23]. This finding adds to the evidence that proteasome inhibitor
resistance can be class-, and, in the case of the vinyl sulfones, even compound-specific. Resis-
tance selections with the AsnEDA compound PKS21004 yielded parasites with high levels of
resistance (>130-fold increases over the sensitive parent), and yielded mutations in the same
residue as one of our WLL-pressure lines (β6 A117D for PKS21004 versus β6 A117V for WLL).
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These differing levels of resistance may be attributable to distinct modes of inhibition for
the AsnEDA compounds versus the vinyl sulfone inhibitors, notably the ability of the latter to
form permanent covalent linkages with the active site threonine of the proteasome beta sub-
units. Vinyl sulfone-mediated inhibition is controlled by an initial reversible binding event
and the subsequent formation of a covalent adduct with the proteasome active site. Mutations
identified in our resistant lines may alter the initial binding of the inhibitor, which would in
turn limit the rate of covalent modification of the active site. However, the potency of these
inhibitors would only be nominally compromised because in the mutant enzyme covalent
adducts would still accumulate over time. For reversible binding compounds such as the
AsnEDA series, these same mutations are predicted to lead to reduced steady-state levels of
inhibitor-bound active sites, causing higher resistance levels. Our data suggest that compounds
with covalent modes of inhibition may thus be preferable over reversible binding inhibitors in
helping to reduce the risk of high-grade resistance.
We also sought to explore potential partner agents for combination therapies including
proteasome inhibitors. Results from isobologram studies revealed potent synergy between
WLL or WLW and five distinct antimalarial agents: DHA, OZ439, methylene blue, b-AP15,
and ESI. Synergy was the most pronounced with early rings, highlighting the value of assessing
drug-drug interactions with synchronized cultures. Our data suggest that these structurally
diverse compounds might share a common feature of generating damaged or misfolded pro-
teins that accumulate as UPS substrates. Given that the UPS is a major regulator of the cell
stress response, we propose that inhibition of the P. falciparum proteasome precludes parasites
from resolving protein damage caused by these compounds, thereby creating synergy. DHA
and OZ439, for instance, are endoperoxide-containing drugs that generate carbon-centered
radical species, which non-specifically alkylate intracellular heme and other biomolecules in
blood-stage parasites [41,42,57,58]. This activity is suspected to increase the burden of mis-
folded and damaged proteins. We confirmed earlier observations of proteasome inhibitor syn-
ergy with DHA [15,21–25]. Leveraging the availability of isogenic K13 WT and mutant
parasites we also showed that synergy was unaffected by K13 sequence. Our studies also
revealed potent synergy between WLL or WLW and OZ439, an ozonide compound related to
ART that is now in human clinical trials [2,59,60].
MB is also of interest for potential combination therapies, as this redox-perturbing drug is
very potent against Plasmodium asexual blood stages and gametocytes and has proven gameto-
cytocidal efficacy in P. falciparum-infected patients [61–63]. Its activity has been attributed in
part to disruption of glutathione (GSH) redox cycling [64]. GSH is an antioxidant that neutral-
izes cellular damage by reactive oxygen species (ROS). The major source of ROS in P. falcipa-
rum is parasite-mediated hemoglobin proteolysis and the oxidation of liberated, reactive
heme. Destabilization of the parasite’s antioxidant defense mechanisms results in widespread
damage to cell membranes, proteins and other molecules [65]. Similar to DHA and OZ439,
treatment with MB might increase the parasite’s reliance on the UPS for clearance of damaged
biomolecules, creating synergy with proteasome inhibitors. Prior experiments have also shown
synergy between MB and ART derivatives, further indicating that both drugs may activate sim-
ilar cellular defense pathways in response to protein damage, including the UPS [66,67].
Of the two experimental compounds that we tested, one, the anti-cancer agent b-AP15, acts
directly on the UPS, inhibiting the activity of proteasome-associated deubiquitinases (DUBs)
that catalyze the deubiquitination of proteasome-targeted substrates prior to their transloca-
tion into the 20S proteolytic machinery [68,69]. Interference with ubiquitin deconjugation
from target substrates prevents polypeptide translocation into the 20S proteasome catalytic
core and abrogates proteasomal degradation [17]. The antimalarial activity of b-AP15 has been
attributed to inhibition of PfUSP14 and/or PfUCH54, two 19S-subunit associated DUBs [68–
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70]. The second compound, ESI, inhibits the UPS-related ER-associated degradation (ERAD)
pathway that mediates the disposal of misfolded ER-resident or trafficked proteins [71,72]. In
ERAD, misfolded proteins are shuttled out of the ER through a retrotranslocation machinery
into the cytoplasm where they are ubiquitinated and subsequently degraded by the proteasome
[72]. In human cancer cell lines, ESI specifically inhibits p97, an AAA-ATPase that is an essen-
tial component of the ER retrotranslocon [73,74], suggesting this as a potential target in Plas-
modium. Synergies observed between our proteasome inhibitors and both ESI and b-AP15 can
likely be attributed to the disruption of two targets in the UPS pathway. Both sets of interac-
tions suggest promising avenues for developing novel combination therapies.
Our data also identified several antimalarial classes that were antagonistic with proteasome
inhibitors. These included inhibitors of hemoglobin metabolism and heme detoxification
(CQ, PPQ and putatively LMF), mitochondrial function (ATQ and DSM265), protein synthe-
sis (AN3661, CHX, DDD107498 and HFG), sodium homeostasis (NITD609), and digestive
vacuole transport processes (ACT-451840) [54,55]. These drugs may antagonize proteasome
inhibitors by reducing the protein degradative burden on the UPS. As an example, attenuating
protein synthesis through translation inhibitors (such as DDD10798 or CHX) could reduce
the parasite’s reliance on the proteasome to eliminate defective nascent proteins and thereby
diminish the impact of proteasome inhibition [16,75].
For the 4-aminoquinolines CQ and PPQ, antagonism of WLL and WLW might be attribut-
able to their inhibition of hemoglobin proteolysis, which occurs at similar concentrations to
their inhibition of hemozoin formation [76]. This may lead to translation attenuation due to a
lack of available amino acid precursors stemming from liberated and digested globin, thereby
reducing dependency on the proteasome and antagonizing its inhibitors. This postulate could
be addressed by studying hemoglobinase inhibitors, such as ALLN and E-64 [45,77]. Further
studies are required to determine whether inhibition of mitochondrial functions (specifically
pyrimidine biosynthesis and maintenance of the electron transport chain, inhibited by
DSM265 and atovaquone respectively) would also antagonize proteasomal inhibitors by atten-
uating protein synthesis.
Our findings that WLL and WLW share a low propensity for selecting for parasite resis-
tance and favorable stage-specificity and synergy profiles provide a compelling case for the
continued development of Plasmodium-selective proteasome inhibitors as antimalarial thera-
peutics. Ongoing efforts are focused on improving selectivity and pharmacological properties
of the lead vinyl sulfone inhibitors. Recently, we reported a new set of optimized peptide vinyl
sulfone inhibitors, chemically related to WLL, which retained their potency and synergy with
DHA and displayed over three orders of magnitude selectivity for the P. falciparum enzyme.
These compounds had improved solubility, metabolic stability, and oral bioavailability, and
were active in a P. berghei rodent malaria model [24]. The data presented herein reveal multi-
ple chemical classes that display synergistic interactions with peptide vinyl sulfones, and high-
light covalent proteasome inhibitors as promising new agents for use in resistance-refractory
combination therapies to treat multidrug-resistant malaria.
Materials and methods
Parasite culture
The P. falciparum Cam3.II and V1/S lines were previously engineered to express WT K13 or
the C580Y or R539T variants [9]. Parasite lines were maintained in RBCs obtained from Inter-
state Blood Bank (Memphis, TN) at 3% hematocrit, in RPMI 1640 medium supplemented with
gentamicin, hypoxanthine, and Albumax II. Cultures were maintained at 37˚C in modular
incubator chambers gassed with 5% CO2, 5% O2 and 90% N2. To obtain highly synchronized
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parasites, predominantly ring-stage cultures were exposed to 5% D-Sorbitol (Sigma-Aldrich)
for 15 min at 37˚C to remove mature parasites. After 36 hr of subsequent culture, multinucle-
ated schizonts were purified over a 75% Percoll (Sigma-Aldrich) gradient or a magnetic-acti-
vated cell sorting (MACS) column (Miltenyi Biotec). Purified schizonts were allowed to invade
fresh RBCs for 3 hr, and early rings (0–3 hr post-invasion) were treated with 5% D-Sorbitol to
remove any remaining schizonts. These synchronized rings were then used for stage-specific
assays. Synchronized trophozoites were harvested 24 hr later.
In vitro determination of IC50 levels
IC50 values were determined by testing parasites against two-fold serial dilutions of antimalar-
ial compounds [48]. Compounds were tested in duplicate in 96-well plates, with the final vol-
ume per well equal to 200 μL. Parasites were seeded at 0.2% parasitemia and 1% hematocrit.
Parasites were either continuously exposed to drugs for 72 hr, or pulsed with drug for 3 hr fol-
lowed by three rounds of washing to remove drug and a further 69 hr of culture in drug-free
medium. Washes were performed by centrifuging 96-well plates at 800×g for 2 minutes to pel-
let cells, removing drug-containing medium, and resuspending in an equal volume of fresh,
drug-free medium. On the third wash, cultures were transferred to a new 96-well plate.
Removal of media and resuspension were performed on a Freedom Evo 100 liquid-handling
instrument (Tecan). After 72 hr, parasites were stained with 1×SYBR Green and 100 nM Mito-
tracker Deep Red (ThermoFisher) and parasitemias were measured on a BD Accuri C6 Plus
Flow Cytometer with a HyperCyt attachment sampling 10,0000–20,000 events per well [78].
Data were analyzed using FlowJo and IC50 values were derived using nonlinear regression
analysis (GraphPad Prism).
Stage-specificity studies
Highly-synchronized parasites were exposed to WLL (150 nM), WLW (2000 nM), DHA (150
nM), or DMSO vehicle control for 1 hr followed by drug washout and further culture. All
stage-specificity tests were concluded 72 hr from the start of the experiment. Assays were per-
formed in duplicate. Parasites were prepared by synchronizing ring stages with 5% D-Sorbitol
and later isolating the schizonts over a 75% Percoll gradient. These schizonts were allowed to
reinvade fresh RBCs at 2% hematocrit. Parasites were tested as purified schizonts, early rings,
mid rings, late rings or trophozoites (~45–47, 0–3, 10–13, 18–21 and 24–27 hr post-invasion,
respectively), and exposed to drug or DMSO vehicle control in 1 mL volumes. Parasites were
seeded at 0.5% parasitemia and 1% hematocrit in a 48-well plate.
Drug-treated parasites were washed as previously described for the RSA0-3h [9]. Briefly, 1
mL cultures were transferred to 15 mL conical tubes, centrifuged at 800×g for 5 minutes to pel-
let cells, and the culture medium containing drug was carefully removed. Cells were subse-
quently resuspended in 10 mL drug-free medium, centrifuged, and the wash medium
removed. Finally, cells were resuspended in 1 mL of fresh drug-free medium, transferred to a
new well, and returned to standard culture conditions for the duration of the assay. Parasite-
mias were measured by flow cytometry and the survival of drug-treated parasites was calcu-
lated as a percent of DMSO-treated control cultures.
Validation of washing protocol for stage-specificity studies
Uninfected RBCs were exposed to WLL (150 nM), WLW (2000 nM), DHA (150 nM) or
DMSO vehicle control for 1 hr, followed by drug washout exactly as above. For each treatment,
20 μL of packed RBCs were exposed to drug, equivalent to 1 mL of a 2% hematocrit complete
media and blood mixture. Synchronized late trophozoites were purified over a MACS column
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(Miltenyi Biotec) following initial synchronization with 5% D-Sorbitol, and were exposed to
drug-pretreated RBCs at 0.5% parasitemia. Experiments were performed in duplicate. Parasite-
mias were measured by flow cytometry 48 hr later and percent growth was calculated relative
to DMSO-treated control cultures.
In vitro generation of drug-resistant lines
To select for WLL- or WLW-resistant parasites, triplicate flasks of 2×109 parasites, each with a
starting parasitemia below 2%, were exposed to these compounds at concentrations of 3× or
5× their IC50 values. Selections were performed on Cam3.II K13WT, Cam3.II K13C580Y, V1/S
K13WT, and V1/S K13C580Y. Drug-containing media was refreshed every day for the first six
days, then every 2–4 days. RBCs were replenished every seven days and volumes were reduced
by half every week starting on day 14. Cultures were monitored by Giemsa staining and
microscopy every day until parasites cleared, then monitored two to three times per week to
detect recrudescence. Selections were maintained for 60 days or until recrudescent parasites
were observed microscopically.
Illumina-based whole-genome sequencing
gDNA was prepared from 0.05% saponin-lysed cultures using a DNeasy Blood and Tissue Kit
(Qiagen). To prepare the sequencing libraries, gDNA was fragmented and amplified with the
Nextera XT kit (Cat. No FC-131–1024, Illumina) using the standard dual index protocol.
Libraries were sequenced on an Illumina HiSeq 2500 using the RapidRun mode [34]. Sequence
reads (2×100 bp) were aligned to the P. falciparum 3D7 reference genome (PlasmoDB v. 13.0)
using the Platypus pipeline and the Genome Analysis Toolkit’s (GATK) HaplotypeCaller was
used to call single nucleotide variants (SNVs), copy number variants (CNVs), or insertion/
deletions (INDELs) [79,80]. SNVs were filtered out if they met the following criteria: ReadPos-
RankSum >8.0 or <−8.0, QUAL <500, Quality by Depth (QD) <2.0, Mapping Quality Rank
Sum<−12.5, or filtered depth (DP)<7. INDELS were filtered out if they met the following cri-
teria: ReadPosRankSum <−20, QUAL <500, QD<2, or DP <7. We also removed mutations
where the read coverage was<5. Variants were annotated using SnpEff [81]. In instances
where drug-selected lines showed sequence heterogeneity, clones were generated by limiting
dilution and the candidate SNVs were confirmed by targeted gene sequencing.
Activity-based probe labeling of the P. falciparum proteasome
Proteasome activity was profiled using the BMV037 active-site probe [26,38]. Synchronized
late schizonts were harvested and lysates were prepared by adding equal volumes of hypotonic
lysis buffer (50 mM Tris pH 7.4, 5 mM MgCl2, 1 mM DTT) to parasite pellets. Lysates were
incubated on ice for 1 hr, with occasional vortexing, then spun at 13,000×rpm for 15 min to
recover supernatants. Protein concentrations were determined using a Bradford assay (Pierce).
Lysates (10 μg) were pre-incubated with each inhibitor for 1 hr at 37˚C prior to adding 10 μM
BMV037 for a further 2 hr at 37˚C. Samples were denatured by adding SDS sample buffer,
then briefly boiled and electrophoresed on a 12% SDS-PAGE gel. Gels were scanned on the
Cy5 channel on a Typhoon Scanner (GE Healthcare). IC50 values were calculated for each
inhibitor for β2 and β5 (WLL) or β2 only (WLW) by quantifying labeled subunits using ImageJ
and normalizing to mock-treated DMSO controls. For these labeling studies with parasite
lysate, inhibitor concentrations (0.5 to 50 μM) were selected based on an earlier study with
BMV037 [21].
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Molecular dynamics and modeling of proteasome mutations
The cryo-EM derived atomic structure of the P. falciparum 20S proteasome (PDB accession
code 5FMG) was used to model the following mutations in silico: A20S in β5, A117V in β6,
S208L in β6, C31Y in β2, C31F β2, and A49E in β2. These models were used to dock WLL or
WLW into the mutant β5 and β2 subunits, respectively. For the β5 and β6 mutations, the struc-
tural consequences of these mutations were examined using molecular dynamics simulations
on models containing only the active site subunits without the WLL ligand. Standard proce-
dures in the AMBER 14 software package (PME MD protocol) were used, namely generation
of topology files for proteins and preparation of AMBER input data using the LeaP module,
development of the hydration model in a periodic water box (TIP3P model of water for explicit
solvent), thermodynamic equilibration of the system and the solvent, and molecular dynamics
calculations at 37˚C using the AMBER ff99bsc0 force field with a simulation time of 10 ns
[82]. The most frequent states for each simulation were used to infer the effects of mutations
on the binding of WLL. In contrast, the β2 mutations were superposed onto the P. falciparum
20S β2β3 dimer structure (PDB accession code 5FMG). These mutated models were prepared
using the Protein Preparation Wizard in Maestro (Schro¨dinger). Structures were minimized
with a harmonic constraint on all heavy atoms (maximum RMSD of 0.3 Å). The binding poses
of WLW in the 20S β2 mutants obtained by superposition were then refined by local minimi-
zation with Prime (Schro¨dinger). This local minimization included WLW as well as all protein
residues within 5 Å of the ligand, and used the variable-dielectric Generalized Born solvation
model. Graphic representations of all resulting models were prepared using the PyMOL
Molecular Graphics System (Schro¨dinger).
Isobologram analyses
Assays were performed with fixed ratios of drug combinations (1:0, 4:1, 2:1, 1:1, 1:2, 1:4, and
0:1), tested in duplicate [45]. Combinations were prepared from 16×IC50 drug stocks and
tested across a range of two-fold dilutions. Assays were conducted with asynchronous cultures
exposed for 72 hr or with tightly synchronized rings or trophozoites (tested at 0–3 hr or 24–27
hr post-invasion, respectively) exposed for 3 hr. Post-pulse drug washouts were conducted as
described above for in vitro determination of IC50 levels. IC50 values were derived for each
compound tested alone, and fractional IC50 (FIC50) values were determined for each com-
pound tested in combination (FIC50 = IC50 of the drug alone/IC50 of the drug in combination)
and plotted for each drug combination. For each combination, the mean of the sums of FIC50
values at each combination (mean SFIC50) was also calculated and the results illustrated using
heat maps.
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Supporting information
S1 Fig. WLL synergizes with multiple classes of structurally and functionally diverse anti-
malarials. Isobolograms of WLL and (in descending order) DHA, OZ439, MB, b-AP15 and
ESI tested on asynchronous parasites and highly synchronized rings and trophozoites. Cam3.II
K13WT or Cam3.II K13C580Y parasites were exposed to compounds mixed at fixed ratios of
Covalent P. falciparum-specific proteasome inhibitors to treat malaria
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007722 June 6, 2019 22 / 29
their individual IC50 values (1:0, 4:1, 2:1, 1:1, 1;2, 1:4, 0:1). Asynchronous parasites were
exposed for 72 hr and parasitemias were determined by flow cytometry. Highly synchronized
rings (0–3 hr post-invasion) or trophozoites (tested 24 hr later) were exposed for 3 hr, followed
by drug washouts and continued culture for 69 hr in drug-free media. Fractional IC50 (FIC50)
values were plotted for each combination and ratio of drugs tested and results were compared
against a hypothetical isobole line illustrating a perfectly additive interaction (dashed line).
Data show results of two independent isobologram assays (shown in different shades), each
performed in duplicate, tested against Cam3.II K13WT (blue) and Cam3.II K13C580Y (red).
Synergy is evidenced by individual FIC50 pairwise values falling below the dashed line of addi-
tive interactions (FIC50 = 1). DHA, dihydroartemisinin; ESI, eeyarestatin I; MB, methylene
blue.
(PDF)
S2 Fig. WLL and WLW antagonize distinct classes of antimalarial compounds. Heat maps
of interactions between the WLL or WLW proteasome inhibitors and distinct antimalarial
agents. Assays used the Cam3.II K13WT and Cam3.II K13C580Y lines. Parasites were exposed to
compounds mixed at fixed ratios of their individual IC50 values (1:0, 4:1, 2:1, 1:1, 1;2, 1:4, 0:1).
Asynchronous parasites were exposed for 72 hr and parasitemias were determined by flow
cytometry. Values represent the mean of the sums of the FIC50 values over the five fixed ratios
of the two test compounds (excluding the 1:0 and 0:1 points). Assays were conducted on two
to four independent occasions in duplicate. CHX, Cyclohexamide; HFG, halofuginone. Means
of the sums of FIC50 (mean SFIC50) values are reported in S13 Table.
(PDF)
S1 Table. Geographic origin and drug resistance genotypes of Plasmodium falciparum
lines.
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S2 Table. WLL and WLW 72 hr IC50 values.
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S3 Table. WLL and WLW 3 hr IC50 values.
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S5 Table. Mean percent growth of synchronized trophozoites exposed to proteasome
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